SCH 900271 is a nicotinic acid derivative designed to treat dyslipidemia. It reduced plasma free fatty acids levels but without significant flushing a side effect common with niacin that limits its usefulness. SCH 900271 is currently in human trials.
This page contains content from the copyrighted Wikipedia article "SCH 900271"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
